Sanofi bets on new CEO to drive sluggish drug sales
In veteran drug salesman Paul Hudson, Sanofi’s 100,000-plus employees are getting a new chief executive who relishes a good commercial fight.
Sanofi loses German patent case against Amgen over cholesterol drug
Germany’s highest civil court rejected French drugmaker Sanofi’s bid to fend off a legal challenge by U.S. rival Amgen against Sanofi’s cholesterol drug Praluent.
Cholesterol-lowering drugs tied to reduced glaucoma risk
High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk.
Waylivra Approved In EU For Treating FCS
Akcea Therapeutics Inc. and Ionis Pharmaceuticals Inc. announced that Waylivra received conditional marketing authorization from the European Commission as the only therapy for FCS.
FDA approves expanded label for Praluent
The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals’ cholesterol drug Praluent as a treatment to cut the risk of heart attacks, stroke and other major cardiovascular events.
Gelesis Granted FDA Clearance to Market PLENITY™ — a New Prescription Aid in Weight Management
Gelesis announced that the United States Food and Drug Administration cleared the biotechnology company’s lead product candidate Plenity (Gelesis100) as an aid in weight management in adults with a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.
Sanofi, Regeneron lose U.S. patent challenge to Amgen cholesterol drug
Amgen Inc. said a U.S. jury confirmed the validity of patents on the biotech company’s cholesterol drug Repatha, rejecting a challenge by Regeneron Pharmaceuticals Inc. and Sanofi SA.
Push-up capacity may predict men’s heart disease risk
The number of push-ups a man can do in the doctor’s office may be a good predictor of his risk of developing heart disease in the coming years, new research suggests.
Sanofi and Regeneron cutting list price of cholesterol drug by 60 percent
Sanofi SA and Regeneron Pharmaceuticals Inc. will slash the U.S. list price of the companies’ potent but expensive cholesterol fighter Praluent by 60 percent.
Statins may help prevent diabetes-related eye problems
Diabetic patients who take statins to treat high cholesterol may get an added benefit: a lower risk of damage to the retina, a new study suggests.
Ad Right Top
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!